A number of investment brokers have recently updated their price targets on shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/03/2015 – Auspex Pharmaceuticals Inc was downgraded to “neutral” by analysts at Ladenburg Thalmann.

03/31/2015 – Auspex Pharmaceuticals Inc was downgraded to “hold” by analysts at Robert W. Baird. They now have a USD 101 price target on the stock.

03/31/2015 – Auspex Pharmaceuticals Inc had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 101 price target on the stock.

03/31/2015 – Auspex Pharmaceuticals Inc was downgraded to “hold” by analysts at Stifel Nicolaus. They now have a USD 101 price target on the stock.

03/30/2015 – Auspex Pharmaceuticals Inc was downgraded to “market perform” by analysts at William Blair. They now have a USD 105 price target on the stock.

03/30/2015 – Auspex Pharmaceuticals Inc was downgraded to “market perform” by analysts at BMO Capital Markets.

12/17/2014 – Auspex Pharmaceuticals Inc had its “outperform” rating reiterated by analysts at Zacks. They now have a USD 60 price target on the stock.

The share price of Auspex Pharmaceuticals Inc (NASDAQ:ASPX) was up +0.00% during the last day of trading, with a day high of 0.00. 0 shares were traded during the last session.

The stock’s 50 day moving average is 94.00 and its 200 day moving average is 59.00.Auspex Pharmaceuticals Inc has a 52-week low of 15.00 and a 52-week high of 101.00.

View other investors thoughts on Auspex Pharmaceuticals Inc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.